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The aim of the present study was to investigate the effect of various transmembrane
ammonium salt gradients and different lipid composition on the loading efficiency of
liposomal formulations of irinotecan hydrochloride (CPT-11), their behavior in vivo and
cytotoxicity. Among ammonium salts studied, ammonium sulfate was successfully used to
load CPT-11 into liposomes with the highest encapsulation efficiency. Subsequently,
liposomal CPT-11 with different lipid composition was prepared by ammonium sulfate
gradient method. CPT-11 can be loaded to a level over 90% into liposomes composed of
soybean phospholipids/cholesterol (SPC-L) or hydrogenated natural soybean phospho-
lipids/cholesterol (HSPC-L). In vitro release profiles were also investigated, indicating that
HSPC-L had a lower release than that in SPC-L. In vivo, encapsulation of CPT-11 in both
liposomal formulations showed higher area under the curve (AUC), a lower rate of clear-
ance (CL) and smaller volume of distribution for CPT-11 than those of irinotecan hydro-
chloride solution (CPT-11-S). However, CL and AUC of 7-ethyl-10-hydroxycamptothecin
(SN-38) were moderately improved in HSPC-L group. Based on the results of comparative
pharmacokinetics of liposomal CPT-11 with different lipid composition, the in vitro cyto-
toxicity of HSPC-L was evaluated with human tumor cell. The result indicated that lipo-
somal CPT-11 showed a great enhancement in vitro cytotoxicity. The results suggested that
entrapment of CPT-11 in liposomes especially in those with high phase-transition tem-
perature lipid by ammonium sulfate gradient would be a promising formulation with a
better in vivo behavior.
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Irinotecan (CPT-11), a topoisomerase I inhibitor, has excellent
antitumor activity against a variety of human xenografts
[1e4]. The clinical introduction of CPT-11 had a significant
impact on cancer treatment, particularly colorectal adeno-
carcinoma and small-cell lung cancers [5e9]. However CPT-11
is discovered to have serious side effects such as myelosup-
pression and gastrointestinal disorders (mainly diarrhea),
which are recognized as constituting dose-limiting toxicity for
this drug [10,11]. CPT-11 has a complicated pharmacologic
profile and is extensively metabolized in vivo to yield a
number of derivatives including the potent metabolite SN-38
which has 100- to 1000-fold more potent antitumor. Further-
more, it is worth mentioning that CPT-11 requires conversion
to SN-38 for optimal activity yet must avoid inactivation via
simple hydrolysis of the requisite lactone configuration to an
inactive carboxylate. After intravenous administration of free
CPT-11, less than 5% of CPT-11 is converted to SN-38, mainly
in the liver. Use of drug delivery technologies focused on
strategies to stabilize the lactone ring of CTP-11 [12,13].
Therefore, it is desired to find an effective drug delivery
system to reduce toxicity and preserve the active form of
the drug.
Recent reports have asserted that the liposomal formula-
tions of CPT-11 can reduce the clearance of CPT-11 in vivo and
increase antitumor activity [14,15]. The liposomal CPT-11
stabilized the lactone ring of CTP-11 as well. The physico-
chemical characteristics of CPT-11 make it amenable to effi-
cient encapsulation in pharmaceutically viable liposome
systems. CPT-11 can be trapped into liposomes with high
encapsulation efficiency by pH-gradient, however, the acidi-
fied liposome can introduce instability by hydrolyzing lipid at
acidic pH during long-term storage. Recently, a loading
method was developed using copper adjusted to neutral pH
with triethanolamine (TEA) without generation of a pH-
gradient [16,17], whereas there is a possibility that serum
copper causes systemic toxicity [18e20].
The transmembrane ammonium salts gradient approach
differs frommost other chemical approaches used for remote
loading of liposomes, since it neither requires preparation of
the liposomes in acidic pH, nor to alkalinize the extra-
liposomal aqueous phase. The stability of the ammonium ion
gradient is related to the low permeability of its counterion,
the anion which also stabilizes CPT-11 accumulation for pro-
longed storage periods. It can eliminate systemic toxicity
caused bymetal ion and load CPT-11 into liposomes with high
encapsulation efficiency.
Now we developed a transmembrane ammonium ion
gradient extensively in loading the amphipathic weak bases
into liposomes to achieve high encapsulation efficiency. As for
this method, we investigated the effect of different lipid
composition and various transmembrane ammonium salt
gradients on the loading efficiency of liposomal formulations.
Characterizations of prepared liposomes in vitro were mainly
measured. Meanwhile, comparative pharmacokinetics of
CPT-11 liposomal formulations and CPT-11 injection (Sol) in
rats were carried out. Nevertheless, few published reports
have investigated in depth the pharmacokinetics of liposomalCPT-11 encapsulated by ammonium salt gradient method.
Also, the study on in vitro cytotoxicity of liposomal CPT-11
was conducted.2. Materials and methods
2.1. Materials
CPT-11 and camptothecin were obtained from Chengdu Lan-
bei Plant Chemical Science and Technology Co., Ltd (Chengdu,
China). SN-38 was bought from Shanghai Junjie Biotechnology
Co., Ltd (Shanghai, China). Hydrogenated natural soybean
phospholipids (HSPC) and soybean phospholipids (SPC) were
purchased from Lipoid Co. (Germany). All other reagents were
of analytical grade and used as received.
2.2. Animals
Wistar male rats weighting between 180 and 220 g were used
for pharmacokinetic study. The animals were provided by
Experimental Animal Center of Shenyang Pharmaceutical
University (Shenyang, China). All experimental procedures
were carried out in accordance with the guidelines of the
Experimental Animal Care and Use Committee of Shenyang
Pharmaceutical University. The rats were fasted overnight
before the experiments and water was available ad libitum
throughout the experiments.
2.3. Synergistic effect of partition coefficient and
different salt gradients on the loading efficiency of CPT-11
into liposomes
1-Octanol was used to represent the biomembrane. The
partition coefficients of CPT-11 between 1-octanol and salt
solutions at 25 Cwere determined by the shake-flaskmethod.
Various salt solutions (200 mM), including ammonium salts of
sulfate ((NH4)2SO4), phytate (NH4-PA), edetate (ETDA-2NH4),
pyrophosphate (NH4PO3), polyphosphate (NH4-APP), chloride
(NH4Cl), citrate (NH4-CA), and acetate (NH4-AC), triethano-
lammonium salts of phytate (TEA-PA) and citrate (TEA-CA),
and copper sulfate (CuSO4), were investigated in this study. 1-
Octanol and salt solution were co-saturated with each other
for 24 h at 25 C prior to use. 1-Octanol (4 volumes) and salt
solution containing irinotecan (1 mg/ml) (1 volume) were
mixed in the screw-capped glass scintillation vials and
equilibrated under constant shaking at 25 C for 24 h. The
aqueous phase was then separated by centrifuging at
3000 rpm for 10 min and the concentration of CPT-11 in this
phase was analyzed by HPLC. The 1-octanol/salt solution
partition coefficients for CPT-11 were calculated.
The solutions of ammonium salts of ETDA-2NH4, NH4PO3,
NH4-APP, NH4-PA, and NH4-CA were prepared by titration of
edetic acid, pyrophosphoric acid, polyphosphoric acid, phytic
acid, and citric acid solutionswith concentrated ammonia and
diluted to a final concentration of 200 mM, respectively. Also,
the solutions of triethanolammonium salts of TEA-PA and
TEA-CAwerepreparedby titrationof phytic acid and citric acid
solutions with TEA and diluted to a final concentration of
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dissolving corresponding commercial salts in water.
Meanwhile, various salts mentioned above were used to
prepare CPT-11 liposomes by transmembrane salt gradient
(shown in section 2.4) and encapsulation efficiency measure-
ments were performed as described in section 2.5.2.
2.4. Preparation of CPT-11 containing liposomes
Lipids (SPC/Chol or HSPC/Chol) were dissolved in chloroform
in a round bottom flask at the required ratio and dried to form
a thin film under reduced pressure on a rotary evaporator,
which was placed in a high vacuum to remove any residual
solvent. Subsequently, the lipid films were hydrated with salt
solution studied above to achieve multilamellar vesicles
(MLVs) with a final lipid concentration of 100 mg/ml. The hy-
drated temperature of SPC/Chol or HSPC/Chol is 40 C and
55 C respectively. Following MLVs were sonicated by a probe
tip sonicator and then passed through the filter of 0.22 mm
pore size, to thereby prepare large unilamellar vesicles (LUVs).
CPT-11 encapsulation into LUVs was achieved by remote
loading method as followed: the external aqueous phase of
LUVs was exchanged, using Sephadex G-50 size exclusion
chromatography, with a 10 mM histidine/10% sucrose solu-
tion. The preformed liposomes were produced. The CPT-11
solution was added to the preformed liposomes and incu-
bated at 60 C for 10 min. After introduction, the sample was
cooled in ice for 15 min. The liposome dispersions were
passed through a 0.22 mm membrane to eliminate any mi-
crobes and then stored at 4e8 C.
2.5. Characteristics of liposomal CPT-11
2.5.1. Particle size measurement
The particle size of prepared liposomes was measured by dy-
namic light scattering using NICOMP 380 submicron particle
size analyzer (PSS, Santa Barbara, CA, USA) with a scattering
angle of 90. The sampleswere dilutedwithphysiological saline
to suitable optical density value prior to measurement.
2.5.2. Encapsulation efficiency measurement
Theseparationof liposomesfromfreeCPT-11wasperformedby
size exclusion chromatography using a Sephadex G-50 column.
After separation, the amount of CPT-11 in liposomes was
determined at 370 nm by ultraviolet spectrophotometer (Uni-
comInstrumentCo., Ltd,China) after lysis of the liposomeswith
Triton X-100. Then the total amount of CPT-11 in liposomal
suspensionwasassayedby the samemethodmentionedabove.
The encapsulation efficiency was calculated.
2.5.3. In vitro release experiments
Because of the easy conversion of CPT-11 into carboxylate
form in neutral medium, PBS with pH 5.0 was chosen as the
release medium in release experiments in vitro. The release
experiments were carried out in an isotonic PBS buffer with
pH 5.0 at 37 C. Briefly, 2.5ml HSPC-L (equivalent to 10mgCPT-
11) was placed in a dialysis membrane bag with a molecular
weight cut-off of 10 kDa, and immersed in 500 ml of PBS me-
dium. The entire systemwas kept at 37 C and stirred at a rate
of 100 rpm. At predetermined time intervals, 3 ml of sampleswere collected, and the amounts of released CPT-11 from li-
posomes were determined at 370 nm by ultraviolet spectro-
photometer, and the accumulated release rate was calculated.
Each release experiment was run three times. The release
experiment of SPC-L was conducted by the same method.
Bring into comparison, the release of CPT-11 solution from the
dialysis bag under the same conditions was also evaluated.
The zero order kinetic equation, first-order kinetic equation,
Higuchi’s equation, and Peppas’s equation were applied to fit
release data.
Simultaneously, the release experiment of HSPC-L with rat
plasma was investigated. The release experiment of CPT-11
solution with rat plasma was also conducted as control
group. Briefly, equal volumes of the sample and rat plasma
were mixed prior to the experiments. Subsequently, experi-
ments were carried out according to the method mentioned
above, except that the amounts of released CPT-11 from li-
posomes were determined by HPLC.
2.5.4. Conversion of liposomal CPT-11 to SN-38 in vitro
CPT-11 liposomes and rat plasma (1:8, v/v) were mixed
together and incubated at 37 C. At indicated time points, the
concentration of SN-38 was evaluated by HPLC. The conver-
sion rate was calculated by the molar ratio of SN-38 to CPT-11
(initialmolar). The conversion of CPT-11 solution to SN-38was
also investigated. The experiments were repeated three times.
2.6. Pharmacokinetic study of CPT-11 liposomes
2.6.1. Analysis of CPT-11 and SN-38 in plasma
A simple HPLC method with fluorescence detection was
developed for the determination of CPT-11 and SN-38 in rat
plasma. The HPLC system (Jasco Corporation, Japan) consisted
of PU-1580 pump with L-7485 fluorescence detector (Hitachi
Co., Japan). HPLC separation was performed in a stainless-
steel Diamonsil C18 column (150  4.6 mm I.D.; 5 mm particle
size; Dikma) and the column temperature was maintained at
30 C. The mobile phase consisted of acetonitrile-50 mM
disodium hydrogen phosphate (30:70, v/v) containing 5 mM
heptanesulphonate, adjusted to pH 3.0 with orthophosphoric
acid. The flow-rate was set at 1.0 ml/min and the injection
volume was 10 ml. The excitation wavelength was set at
556 nm, and the emission wavelength was 380 nm. Both
concentrations of CPT-11 and SN-38 were calculated from the
ratio of their peak areas to that of the I.S. Additionally, line-
arity, extraction recovery, precision and accuracywere carried
out in method validation. The working solutions of CPT-11,
SN-38 and CPT (I.S.) were prepared according to Hidetaka
Sumiyoshi et al. [21].
2.6.2. Drug administration and sample preparation
Wistar ratswere randomly divided into three groups, theHSPC-
L, SPC-L, andSol groupandeachgroupcontainingfive rats. Each
group was administrated at a dose of 20mg/kg via the tail vein.
After dosing, blood samples were collected at predetermined
time intervals. Plasma was separated immediately by centrifu-
gation with low temperature and 100 ml was collected for anal-
ysis byHPLC. Briefly, 100 ml I.S. solution (CPT, 1 mg/ml) and 300 ml
acidified methanol (methanol-hydrochloride (9:1), v/v) were
added to100 ml plasma sequentially. All solutionswere cooled in
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and separated by centrifugation at 14,000 rpm for 10 min.
Finally, the10ml supernatantwas injected into theHPLCsystem.
2.6.3. Data analysis
The data were analyzed by DAS version 2.0 software (Mathe-
matical Pharmacology Professional Committee of China,
Shanghai, China). The main pharmacokinetic parameters
were calculated. A statistical comparison of the pharmacoki-
netic parameters was conducted using Student’s t-test and
one-way analysis of variance (ANOVA). The significance level
was set to be 0.05.
2.7. In vitro cytotoxicity
Hela (cervical), Hos (osteosarcoma), BGC-823 (stomach), MCF-7
(breast) were used to investigated the in vitro cytotoxicity of
liposomal CPT-11. The cells were maintained in RPMI1640 cul-
ture medium (Hos in MEM) in tissue culture flasks in a humidi-
fied incubator at 37 C in an atmosphere of 95% air and 5% CO2.
Medium was changed 3 times a week and cells were passaged
using trypsin/EDTA. For dose-dependent cytotoxicity assays,
Cells were seeded in 96-well plates at 3000 cells/well with 3
replicates and pre-incubated for 24 h.Mediawere replacedwith
freshmedium. And then predetermined amounts of CPT-l1 and
liposomal CPT-11. The in vitro cytotoxicities of CPT-l1 and
liposomal CPT-11 were determined using MTT assay.3. Results and discussion
3.1. Synergistic effect of partition coefficient and
different salt gradients on the loading efficiency of CPT-11
into liposomes
Generally, it was considered that the partition coefficient of
drug in 1-octanol and water (P-value) is an index to estimate
whether the drugs can be encapsulated in liposomes easily or
not. The hydrophilic (Log P < 0.3) or lipophilic (Log P > 4.5)
drugs can be encapsulated in liposomes successfully and
show the stable physicochemical characteristics [22]. Though
the Log P octanol/water for CPT-11 was lower than 0.3
(showed in Table 1), CPT-11, a drug of amphipathic weak base,Table 1 e The octanol/aqueous solution partition coefficients f
Octanol/aqueous solutions Partition coeffi
Octanol/ammonium polyphosphate 31.27
Octanol/ammonium pyrophosphate 21.97
Octanol/ammonium phytate 15.84
Octanol/ammonium chloride 10.16
Octanol/ammonium EDTA 9.91
Octanol/ammonium citrate 8.57
Octanol/phytic acid (adjust pH to 6.5 with TEA) 7.26
Octanol/ammonium acetate 5.76
Octanol/citric acid (adjust pH to 6.5 with TEA) 4.64
Octanol/citric acid (adjust pH to 6.5 with TEA) 4.64
Octanol/CuSO4 1.72
Octanol/ammonium sulfate 1.63
Octanol/water 0.355can not be trapped into liposomes with high encapsulation
efficiency by passive loading method. As the partition coeffi-
cient of amphipathic weak base between 1-octanol and water
was prone to be influenced by the pH and ionic strength of
medium. Thus, CPT-11 was a good candidate to be trapped
into liposomes by remote loading methods. The octanol/me-
dium partition coefficient and state of the drug in intra-
liposomes may serve as crucial factors affecting the loading
efficiency of drug into liposomes [23,24]. Thus, the effect of
octanol/salt solution partition coefficient for CPT-11 and type
of anion of salt on the encapsulation efficiency of CPT-11 li-
posomes were both investigated in this study.
AsshowninTable1, theLogpartitioncoefficient(LogP) values
for CPT-11 ranging from 0.21 to 1.50, indicating that the sort of
salt solution could affect on the octanol/salt solution partition
coefficient. Additionally, the Log P for CPT-11 in octanol/ammo-
nium sulfate solution was the smallest, and the encapsulation
efficiencywas thehighest.Whereas, no regular relationshipwas
observed between the Log P values and the encapsulation effi-
ciency. It was suggested that partition coefficient for CPT-11was
not the only factor affecting the encapsulation efficiency of li-
posomes in remote loading method. Ammonium salt anion,
another factor, was found to influence on the encapsulation ef-
ficiency and the leakage of CPT-11 liposomes.
The role of ammonium salt anion is not only loading the
amphipathic weak base but rather to control the stability of
loading and the release rate of the amphipathic weak base
from the liposomes to the external aqueous phase. Twomajor
factors may influence the role of the ammonium salt anion.
Firstly, their ability to induce precipitation/crystallization/
gelation in the intraliposome aqueous phase, and secondly,
their effect on the membrane/buffer or 1-octanol/buffer
partition coefficient of the amphipathic weak base [24].
Among low molecular weight anions (inorganic and organic)
used to achieve ammonium ion-drive loading, the order of
loading stability for most amphipathic weak bases studied is
sulfate> citrate> phosphate> chloride> glucuronate [25,26].
However, the results (showed in Table 1) in this study
demonstrated that the order of loading stability for CPT-11
was sulfate > EDTA > phosphate > chloride > citrate > ace-
tate, which might be concerned with the property of the drug.
On the other hand, the encapsulation efficiency of lipo-
somes prepared by triethanolammonium salts gradient wasor CPT-11.
cients (P) Log P Encapsulation efficiency (%)
1.50 81.67
1.34 64.39
1.20 84.50
1.01 79.18
0.996 87.50
0.93 16.20
0.86 4.16
0.76 4.38
0.67 2.42
0.67 2.42
0.24 80.53
0.21 90.42
0.45 e
Fig. 1 e Release profiles of CPT-11 from SPC-L, HSPC-L and
CPT-11-S in PBS (pH 5.0) (n [ 3, mean ± SD).
Fig. 2 e Release profiles of CPT-11 from HSPC-L, CPT-11-S
with rat plasma in PBS (pH 5.0) (n [ 3, mean ± SD).
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attributed to the different permeability coefficients of the
neutral ammonia and TEA. The higher permeability coeffi-
cient of neutral ammonia leads to fast diffusion of the NH3 to
the extraliposomal medium and a more stable pH-gradient is
formed [27]. Therefore, transmembrane ammonium ion
gradient was used to entrap the CPT-11 into liposomes.
Furthermore, high encapsulation efficiency (80.53%) of
CPT-11 liposomes can be also obtained by transmembrane
copper sulfate gradient. The reasons may be as follows: the
lower solubility of the CPT-11 sulfate salt formed in the
intraliposomal aqueous phase; the CPT-11 can complex the
transition metal copper and then such complexation can
promote drug loading into liposomes [28]. However, the
toxicity of transition metal was inscrutable in vivo.
Base on these observations, lower octanol/salt solution
partition coefficient and lower permeability coefficient of the
anion through lipid bilayers were crucial factors in obtaining
intraliposomal accumulation of CPT-11. An additional reason
for having stable CPT-11 accumulation is the lower solubility
of the CPT-11 salt formed in the intraliposomal aqueous
phase. The Log P for CPT-11 in octanol/ammonium sulfate
solution was the smallest, and the encapsulation efficiency
was the highest. Therefore, transmembrane ammonium sul-
fate gradient method was chosen to prepare the CPT-11 lipo-
somes. The encapsulation efficiency of CPT-11 liposomes in
this study could reach over 90%.
3.2. Encapsulation efficiency and particle size
distribution of liposomes
CPT-11, a drug of amphipathic weak base (pKa ¼ 8.1), can be
trapped into liposomes with high encapsulation efficiency by
remote loading methods including pH-gradient, trans-
membrane ammonium ion gradient, and transition metal ion
gradient [29e32]. Becauseof somedisadvantages inpH-gradient
andmetal ion gradient [28,33], transmembrane ammonium ion
gradient has been developed extensively in loading the amphi-
pathicweakbases into liposomes to achievehigh encapsulation
efficiency. In this paper, transmembrane ammonium ion
gradient was used to entrap the drug into liposomes.
The encapsulation efficiency of SPC-L and HSPC-L was
91.68% and 95.23%, respectively. It is thus clear that CPT-11
can be trapped into liposomes with high encapsulation effi-
ciency by transmembrane ammonium ion gradient method.
The mean diameter of SPC-L and HSPC-L possessed92.2  45.9 nm, 98.3  52.2 nm, individually, measured by
dynamic light scattering.3.3. In vitro release experiments
Accumulated release profiles of CPT-11-S, SPC-L, and HSPC-L
were shown in Fig. 1. It could be achieved from the profiles
that the accumulated release percentage of CPT-11-S reached
83.13  2.77% at 4 h, while it demonstrated merely
43.57  3.87% and 2.68  0.55%, respectively, for SPC-L and
HSPC-L. The presence of the dialysis bag did not significantly
affect the release rate of CPT-11. It was obvious that the
release of CPT-11 from SPC-L was faster than that from HSPC-
L, which could be due to the lower phase-transition temper-
ature of SPC than that of HSPC. It was evident that HSPC-L has
a sustained release in vitro.
The accumulated release profiles of CPT-11-S and HSPC-L,
both with rat plasma, were shown in Fig. 2. A quicker release
behavior of CPT-11 was observed in HSPC-L with rat plasma
when compared with that in HSPC-L with PBS. It was thus
evident that plasma could accelerate the release of CPT-11 from
liposomes. The biological fate of liposomesmight be affectedby
plasma factors. As various plasma components could influence
the stability of liposomes and high density lipoprotein (HDL)
was the essential one. Apolipoprotein A-1 (apoA-1)was liable to
fall off from HDL, and interacted with phospholipids of lipo-
somes. Thatwas to say, exchange of apoA-1 and phospholipids
occurred between HDL and liposomes, resulting the formation
ofholeonthe liposomalmembranes.Additionally,hydrolysisof
phospholipidswas causedbyphospholipaseexisting inplasma,
and a serum albumin-liposome complex was formed by the
interaction of serum albuminwith phospholipids of liposomes,
which would decrease the stability of liposomes [34]. In addi-
tion, the different release patterns were also observed, the best
fit with higher correlation coefficient was found in release data
ofHSPC-Lwith Peppas’s equation,while the release behavior of
HSPC-L at the presence of plasma was fit to the Higuchi’s
equation. The release data of SPC-L were best fit to first-order
kinetic equation. The equations were shown as follows:
Ln Q ¼ 1:06 Ln t 0:37; r ¼ 0:9952 ðPeppas’s equationÞ
Q ¼ 15:67 t1=2  3:64; r ¼ 0:9969 ðHiguchi’s equationÞ
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¼ 0:9761 ðfirst order kinetic equationÞ
3.4. Conversion of liposomal CPT-11 to SN-38 in vitro
Theprofilesof the conversionpercentageof SN-38 fromCPT-11
in rat plasma in vitro for HSPC-L and CPT-11-S were shown in
Fig. 3. It was indicated that the conversion of SN-38 from CPT-
11 in HSPC-L was slightly less than that in CPT-11-S group, but
there were no significant statistical differences (P > 0.05) be-
tween the two groups. It was suspected that the conversion of
SN-38 from CPT-11 also existed in the membranes of lipo-
somes, which have been reported by Y. Sadzuka [35]. Though
the conversion of SN-38 occurred, SN-38was still entrapped in
the intraliposomes. In this way, SN-38 could be refrained from
metabolization by enzyme systems in plasma and high con-
centration of SN-38 was maintained simultaneously.3.5. Pharmacokinetic study of CPT-11 liposomes
3.5.1. Assay validation
HPLC-Fluorescencemethodwas used for the determination of
CPT-11 and its metabolite SN-38 in plasma, and the results of
validation were as follows:
The CPT-11, SN-38 and CPT were extracted from plasma by
a methanol extraction, and their recoveries were over 90%.
The mean  SD absolute recovery of the I.S. (CPT 1 mg/ml
plasma) was 99.33  1.74%. The range of selected CPT-11
concentration was so wide that two standard curves of CPT-
11 were established. The standard curve was established by
plotting the ratio of the peak area to that of CPT against the
concentration injected. Good standard curves were obtained
for CPT-11 and SN-38, ranging from 20 to 1000 ng/ml,
600e24,000 ng/ml, and 2e200 ng/ml, respectively, which were
sufficient for the pharmacokinetic studies of CPT-11. The
lower limits of quantitation (LLQ) for CPT-11 and SN-38 were
20 and 2 ng/ml, respectively. Thewithin-day and between-day
reproducibility of the assay for CPT-11 and SN-38 were
investigated. Both the precision and accuracy of this method
were acceptable.
CPT-11was easy to be converted into SN-38 in the presence
of carboxylesterases existing in plasma at high level [36].
Therefore, immediate pretreatments were required for bloodFig. 3 e The profiles of conversion percentage of SN-38
from CPT-11 in vitro for HSPC-L and CPT-11-S in rat
plasma.samples, which can inhibit the conversion of CPT-11 into SN-
38 in plasma, so that the concentrations of CPT-11 and SN-38
in plasma can be determined with high accuracy. In addition,
the aim of acidifying samples was to transform the carbox-
ylate forms of CPT-11 and SN-38 to the closed lactone forms,
and determine the total concentrations of CPT-11 and SN-38
in plasma.
3.5.2. Pharmacokinetics
The pharmacokinetic behavior of CPT-11 liposomes was
investigated and compared with that of CPT-11 solution. Also,
comparative pharmacokinetics of SPC-L and HSPC-L were
conducted.
The plasma concentration versus time profiles of CPT-11
and SN-38 obtained after i.v. injection of SPC-L, HSPC-L, and
Sol in rats were showed in Figs. 4 and 5, respectively. As
shown in Figs. 4 and 5, there were several striking differences
in pharmacokinetic properties between the liposomal CPT-11
formulations and CPT-11 solution. In the plasma, the CPT-11
concentrations at 5 min, 15 min, 0.5 h, and 1 h after injec-
tion of the SPC-L group increased 12.5-fold (P < 0.01), 6.3-fold
(P < 0.01), 3.2-fold (P < 0.01), and 2.1-fold (P < 0.01), respec-
tively, compared with that in the Sol group, but there were no
significant differences ranging from 1.5 h to 12 h (P > 0.05).
CPT-11 concentrations in plasma were below the detection
limit at 24 h after dosing in both groups of SPC-L and Sol. In
addition, the plasma concentrations of SN-38 were nearly the
same (P > 0.05) at all indicated time between the SPC-L and
Sol. Nevertheless, the plasma concentrations of CPT-11 were
higher in HSPC-L than that in Sol or SPC-L at all time points.
The CPT-11 concentration in plasma at 5 min, 15 min, 0.5 h,
and 1 h after injection of the HSPC-L group was 70-fold
(P < 0.01), 57-fold (P < 0.01), 43-fold (P < 0.01), and 38-fold
(P < 0.01), respectively, higher than that in the Sol group.
Moreover, the plasma concentrations of SN-38 were higher in
HSPC-L than that in Sol or SPC-L at all time points especially
ranging from 2 to 24 h.
The main pharmacokinetic parameters were shown in
Table 2. It was exhibited that HSPC-L had a 32.6-fold (P < 0.01)
increase in the AUC of CPT-11 when compared to Sol, while
AUC for SPC-L was 3.3-fold (P < 0.01) greater than that of Sol.Fig. 4 e Plasma concentration of CPT-11 versus time curves
after intravenous administration of HSPC-L, SPC-L and Sol,
respectively (n [ 5, mean ± SD).
Fig. 5 e Plasma concentration of SN-38 versus time curves
after intravenous administration of HSPC-L, SPC-L and Sol,
respectively (n [ 5, mean ± SD).
Table 3 e In vitro cytotoxic activity of liposomal CPT-11
and CPT-11 on different human tumor cells (IC50, n ‡ 3).
Cancer cells Means  SD
Liposomal CPT-11 (mg/ml) CPT-11 (mg/ml)
Hela 3.118  2.028a 16.08  5.446
HOS 5.806  3.001a 19.51  6.083
BGC-823 2.115  0.366a >60
MCF-7 2.807  0.346a 16.265  6.170
a P < 0.05 compared to the CPT-11.
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was 3.2 (P < 0.01) and 3.6 times (P < 0.01), respectively, lower
than that in the Sol group. Furthermore, it was indicated that
HSPC-L had a 29.5-fold and 29.4-fold decrease in the CL and V
of CPT-11, respectively, compared with the Sol group. On the
other hand, the t1/2 of CPT-11 did not differ significantly
between the liposomal formulations (HSPC-L, SPC-L) and so-
lution (P> 0.05). Comparedwith SPC-L, HSPC-L exhibited 10.5-
fold higher AUC of CPT-11, 8.8-fold lower of CL (P < 0.01), and
8.2-fold lower of V (P< 0.01). The pharmacokinetic parameters
of SN-38 were comparable in both groups of SPC-L and Sol
(P < 0.05). However, HSPC-L demonstrated 3.03- and 3.8-fold
higher AUC of SN-38 (P < 0.05), respectively, than those in
Sol and SPC-L group. Meanwhile, HSPC-L had a 2.57- and 3.12-
fold decrease in clearance of SN-38 (P < 0.05), when compared
with Sol and SPC-L group, respectively.
It was concluded that liposomes, as carriers of CPT-11, can
significantly improve AUC, decrease CL and V of CPT-11.
HSPC-L demonstrated superior pharmacokinetic behavior of
CPT-11 or SN-38, when compared with SPC-L or Sol.
In vivo pharmacokinetics behavior differences between
free and liposomal CPT-11 might be due to the differences of
their stability in vivo. Compared with liposomal CPT-11, the
free one, after i.v administration, eliminates fast by hydrolysis
in plasma, transport to surrounding tissues and its elimina-
tion via the kidney. Simultaneously, owing to its encapsula-
tion in the inner phase of liposomes, liposomal CPT-11 couldTable 2 e Themain pharmacokinetic parameters of CPT-11 and
rats, respectively (n[ 5).
Parameters AUC0eN (mg/ml h)
CPT-11 (mean  SD) HSPC-L 306.24  133.17a
SPC-L 29.22  4.99a
Sol 2.17  0.59
SN-38 (mean  SD) HSPC-L 0.88  0.37b
SPC-L 0.23  0.05
Sol 0.29  0.07
a P < 0.01 compared to the Sol.
b P < 0.05 compared to the Sol.escape hydrolysis in vivo after administration, which would
result in higher plasma concentration of CPT-11 in active
form. The following possible reasons can be explained for the
different in vivo behaviors between HSPC-L and SPC-L. Lipo-
somes with different lipid composition should have different
in vivo behavior. The phase-transition temperature (about
20 C) of SPCwas lower than body temperature (37 C), which
would decrease the stability of SPC-L after administration,
resulting in quick release of CPT-11. On the contrary, HSPC
with high phase-transition temperatures (about 50 C) should
slow the leakage of CPT-11 from intraliposomes and warrant
high drug level in blood circulation system.
On the other hand, the conversion of SN-38 occurring in
CPT-11 liposomes (as shown in Fig. 3) and the pharmacoki-
netic behavior of CPT-11 liposomes, suggested that CPT-11, a
pro-drug, can also be trapped effectively in liposomes. How-
ever, the blood circulation of CPT-11 was not improved greatly
by liposomal formulation. The order of elimination t1/2 value
for CPT-11 and SN-38 was HSPC-L > Sol > SPC-L, but there is
no significant difference between those values, suggested that
the elimination of CPT-11 liposomes from blood circulation is
still rapid. It might be due to that unmodified CPT-11 lipo-
somes were unavoidable to be recognized by alternative
pathways of complement activation and captured by macro-
phages in RES organs. Therefore, the next study point in this
investigation may be the modification on the surface of the
liposomes to achieve an improvement in both circulation time
and plasma levels of CPT-11 and SN-38.
3.6. In vitro cytotoxicity of liposomal CPT-11
The biological activity of liposomal CPT-11 was investigated
and compared with that of CPT-11 using Hela, Hos, BGC-823
and MCF-7. Liposome-entrapped CPT-11 showed a greatSN-38 after i.v. administration of HSPC-L, SPC-L and Sol to
t1/2 (h) V (l/kg) CL (l/h/kg)
1.81  0.91 1.7  0.05a 0.08  0.03a
1.36  0.40 1.40  0.60a 0.70  0.12a
1.59  0.57 5.04  1.69 2.27  0.66
7.52  4.24 243.87  70.13 28.35  17.72a
3.38  0.60 426.96  89.07 88.48  15.40
4.04  1.43 421.43  175.92 72.73  15.49
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 3 0 3e3 1 1310increased cytotoxicity versus CPT-11. IC50 value against Hela,
Hos, BGC-823 and MCF-7 were 3.12, 5.81, 2,12 and 2.81 mg/ml
for liposomal CPT-11 and 16.08, 19.51, >60, and 16.27 for CPT-
11 (show in Table 3). The IC50 value of 48 exposure to liposome
containing CPT-11 is 5.15-fold, 3.36-fold, more than 28.37-fold
and 5.79-fold greater than free drug. The increased cytotox-
icity derived from encapsulation may arise from preserving
the active form of the CPT-11. Because the pH of mediumwas
near physiological pH value and CPT-11 hydrolyzed to yield
the inactive carboxylate species. But on the contrary, the in-
ternal acidic environment of the liposome limits hydrolysis of
the lactone ring of camptothecins to the inactive carboxyl
form. The CPT released from the liposomes into the culture
medium slowly andmaintained the effective concentration of
the active form of the CPT-11 for a long time. But hydrolysis of
free CPT-11 yielded a high percentage of inactive carboxyl
form drug. So greatly enhanced cytotoxicity was obtained by
encapsulating CPT-11 in liposome.4. Conclusion
In this study, CPT-11 was entrapped into liposomes success-
fully by transmembrane ammonium sulfate gradient, pos-
sessing high encapsulation efficiency and sustained release
in vitro. In vivo, encapsulation of CPT-11 in liposomes showed
higher AUC, a lower rate of clearance and smaller volume of
distribution for CPT-11 than those in Sol. The rate of clearance
and AUC of SN-38 were improved in HSPC-L, but no obvious
difference was observed in the pharmacokinetic parameters
of SN-38 between SPC-L and Sol. HSPC-L demonstrated
superior pharmacokinetic behavior of CPT-11 and SN-38,
compared with SPC-L and Sol. The increased cytotoxicity of
liposomesmay be due to it can preservingmore active form of
the CPT-11. It appears that entrapment CPT-11 in liposomes
especially in those with high phase-transition temperature by
transmembrane ammonium salt gradient would be a prom-
ising formulation with a better in vivo behavior.r e f e r e n c e s
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